Summary.-The paper presents a detailed comparison of the anatomical distribution and frequency of clinically evident metastases in 152 cases of osteosarcoma, and autopsy findings in 43 cases. The behaviour of long bone tumours is contrasted with those arising elsewhere, which tend to metastasize less widely because of early death from effects of the primary tumour. In both clinical and autopsy series long bone tumours produced lung metastases (LM) in over 90% of patients dying with metastases, but the terminal frequency of extra-pulmonary metastases (EPM) rises from a clinical level of 33% to 83% at autopsy.
There was little difference between tumours of the major long bones in the frequency of either LM or EPM, but EPM from the humerus tended to be fewer and sited above the diaphragm and from the femur below it. EPM most often involved other bones, notably vertebrae and pelvis. Not more than 10% of tumours invaded regional lymph nodes but terminally a quarter of the long bone tumours had metastasized to heart and abdomen. The infrequency of metastases in muscle was confirmed.
The median time for LM was 5-6 months after starting treatment, for EPM 9-10. months. First metastases after 24 months were infrequent, especially in children. With delay in the appearance of metastases, whether LM or EPM, post-metastatic survival lengthened. Neither age, sex nor mode of treatment of the primary notably affected metastatic frequency, although recurrences were much more numerous when radiotherapy, even with high dosage, was the definitive treatment. Local recurrence usually appeared within 6-8 months and was shown to lead to increased frequency of osseous metastases. It is suggested that terminal dissemination may often be tertiary but not always from a pulmonary secondary. THE PAST 30 years' experience of the treatment of osteosarcoma shows universally bad results for any large series of cases. This is due both to the intrinsic limitations of current therapeutic methods and to concentration upon control or destruction of the primary tumour only, although it becomes increasingly obvious that the overwhelming lethal factor is distant metastatic growth, particularly in the lungs. With tumours of long bones, which comprise the great majority of osteosarcomata presenting in young people, lung secondaries are almost invariably the cause of death, even though metastases in other sites are not infrequent and are also potentially lethal.
The explosion in diversity and scope of chemotherapy in the last decade is already producing better prognoses for some solid tumours. It is hoped that the use of cytotoxic drugs in the treatment of osteosarcoma may prolong the disease-free survival in this tumour also. Planned treatment along these lines requires a precise knowledge of tumour behaviour, especially of the dominating metastatic activity. We present an analytical study of Tables I and VII) The records used for this study are essentially the same as for a previous paper (Price and Jeffree, 1973) Metastases found at autopsy (Fig. 3 , Tables  III and VIII) Only 10 of the BTR patients came to autopsy. One died from coronary artery disease 12 years after high thigh amputation for a tumour of lower femur: no evidence of tumour was found at autopsy. In the other 9 cases-6 osteosarcomata of long bones and 3 of other bones-the clinical evidence of metastases may be compared with the autopsy findings (Fig. 3) (Table III) show a frequency of EPM at death of 83%. Thus radical or palliative treatment for EPM will be required in 33-83% of cases with metastases, approaching the higher figure sub-terminally. Table I shows the anatomical distribution of clinical metastases, and data from 29 autopsies are given in Table III.  Table II summarizes the clinical incidence of LM and EPM from tumours of different sites. The site of the primary tumour does not materially affect the frequency of metastases but the frequency of clinical EPM is greatest for the femur, with a tendency to more widespread dissemination and involvement of other bones, particularly pelvis and spine, which is also apparent in the autopsy records. Figure 4 shows the time of presentation of clinical metastases. The vast majority, both LM and EPM, appeared within 2 years of starting treatment, with a median of [5] [6] (Fig. 8) . Table VIII is an analysis of metastatic sites recorded for 14 autopsied cases of osteosarcoma of other bones. Three (21%) had no macroscopic metastases. LM were noted in 10 (71 %) and osseous metastases in 5 (35%). The general pattern of EPM resembles that of the long bone tumours but at a lower level throughout. Osseous metastases were found only in skull, ribs and vertebrae. One patient, not included in Table VIII , died from a tumour embolism of the right subclavian vein, right auricle and pulmonary artery, post-operative after scapulectomy, but without other metastases.
Ultimate causes of death from o8teosarcoma
Most patients die at home, without adequate medical records, and the following information is derived from autopsy reports. As with many forms of cancer, the commonest terminal factor is " malignant cachexia "-emaciation and asthenia, with or without anaemia, with multiple LM and EPM and often a large uncontrolled primary tumour. About 90% have multiple bilateral LM which are sometimes immense. Rather less than half have pleural effusions with some degree of lung collapse, this being commoner than bronchopneumonia or bronchitis. About a third have metastatic or thrombotic/embolic cardiovascular disease and about a quarter may have obstruction or infection of the urinary tract. Other less frequent causes of death are haemorrhage into a lung or pleural cavity, septicaemia, tracheal obstruction from tumour metastatic in the thyroid and intestinal obstruction due to abdominal secondaries.
Sex and age distribution and metastases
The figures given in Table IX show no significant differences between the sexes for metastases either from tumours 2-20 months), which is similar to the median for LM and slightly longer than the mean recurrence time of 3-7 months reported by Jenkin (1973) . Only 2 local recurrences occurred after 12 months.
Figures 7 and 8 compare the frequency of metastases in 28 cases with local recurrence and 82 without (7 patients with and 5 without recurrence died with no recorded metastases, and there were 2, not included in either group, where the primary showed no response to treatment). There are no marked differences between the 2 groups for the first 6 months; after this Fig. 7 shows an increase in metastatic frequency related to local recurrence, and a second rise after 18 months. Figure 8 shows that the difference is mainly due to a marked increase in bone metastases from tumours with recurrence. This is statistically significant at 24 months (P < 0-05).
It would seem that nearly all metastases which are clinically manifest within 6 months of starting treatment are already seeded at that time. This includes most lung metastases but only a small proportion of osseous metastases, and there is prolonged dissemination so long as active tumour remains in the body.
Local recurrence occurred in 18/68 tumours of femur (26%) 5/32 tumours of tibia (16%) 3/5 tumours of fibula (60%) 9/19 tumours of humerus (47%) (One tumour of fibula recurred after local excision, was treated by radiotherapy and again recurred; it was then amputated.) Only the difference between humerus and tibia is statistically significant (P < 0 02) but the greater frequency of local recurrence in the humerus may be attributed to the larger proportion treated by radiotherapy, which has a positive correlation with recurrence:
Humerus, radiotherapy (lamputation (16/19 (84%); recurrence 47%.
Femur, radiotherapy (±amputation) 40/68 (58%); recurrence 26%.
Tibia, radiotherapy (±amputation) 11/32 (31%); recurrence 16%. It is peculiar that the humerus, with a high local recurrence rate, has the lowest rate of EPM, but those which do occur are almost entirely osseous, thus following the trend shown in Fig. 8 
* 10 of these 13 had limb ablation for tumour recurrence. In addition, the tumour of fibula with recurrence after excision was then treated by radiotherapy and later amputated for further tumour activity. As already shown by survival curves (Price and Jeffree, 1973) , after 2 years metastatic frequency diminishes and individual prognosis improves.
With the median time for LM at 5-6 months, the " Cade " method alone can never cure more than 50% of patients.
All published series agree on this time for LM, whether treatment has been "Cade " or ablation.
After the median time for LM, metastases are less rapidly lethal, probably owing to their slower growth, which may reflect enhanced host resistance (Table V) . This less aggressive behaviour of later metastases has been reported for other cancers-breast, thyroid, kidney and seminoma. Ifit is due to a host-immune reaction, this must be systemic and not localized to any particular organ or type of tissue, since it holds good not only for LM but for EPM in a number of different sites.
Metastases in special sites
Other bones.-As with metastatic carcinoma, vertebrae and pelvis are most frequently involved. Osseous metastases were reported clinically or radiographically for 18% of the long bone tumours, closely conforming with the 14% of McKenna et al. (1966) . Lockshin and Higgins (1966) found 41% with bone metastases among 22 patients dying in hospital who were examined terminally by radiography or autopsy. This agrees well with the 48% reported here with osseous metastases at autopsy. Owing to their shorter average survival, patients with primary tumours of other bones show fewer osseous metastases either clinically (7%) or at autopsy (36%).
Heart metastases.-These are subterminal events, being found in our series only at autopsy; if they are secondaries, they must grow more slowly than metastases in other sites. Yet in only 2 of 9 cases did they appear to be tertiary from lung secondaries, in the other 7 they may have been true secondaries or tertiary from large metastases in, for example, the pelvis. Autopsy records suggest that, even with advanced modern surgical techniques, it would seldom, if ever, be possible to remove a heart metastasis with any good hope of success. Possibly their late effect upon cardiac function may rarely be misinterpreted as drug cardiotoxicity.
Cerebral metastases.-These were recorded at autopsy for 3 long bone tumours (one femur, 2 tibia), the sites involved being respectively surface of temporal lobe, cerebellum and left frontal lobe; 6 separate unspecified sites. Two patients also had multiple LM. Surgical removal of brain metastases may deserve careful consideration in the absence of clinical metastases elsewhere.
Muscle.-As with other cancers, the infrequency of muscular metastases (even in the heart) is noteworthy. Yet the wide spectrum of metastases suggests that tumour cells must also reach muscle, but find the environment unsuitable for further growth. Why this is so is not known but it surely merits further careful experimental investigation. The spleen likewise is seldom involved.
Lymph node metastases. Trifaud and Meary, 1972) . By contrast, the clinical appearance of osseous metastases is significantly increased by local tumour recurrence, suggesting that only about one-third of these have been seeded at the time of first treatment. Similarly in Ewing's sarcoma, which metastasizes freely to other bones, local recurrence is often associated with further metastatic spread (Macintosh, Price and Jeffree, 1975) .
Longer post--metastatic survival after later metastases (Fig. 5) This relationship agrees with the similar findings of Joseph, Morton and Adkins (1971) who noted positive correlations between the time of onset of metastases, the estimated tumour doubling time, and length of survival.
Mode of spread
The general pattern found in both clinical and autopsy studies supports the present view that the venous pathway of tumour dissemination is usual. Bearing in mind that in addition to the caval vessels there is a wide network of the vertebral vein system (Batson, 1957) in which reversal of blood flow may take place, it is easy to comprehend how limb tumours may spread to the axial and girdle bones and elsewlhere. There is some indication that leg tumours tend to metastasize below the diaphragm and arm tumours above it, and that osteosarcoma of humerus is less likely to metastasize than that of femur, but secondaries from either limb may appear almost anywhere. Osteosarcoma of other bones conforms to the long bone pattern apart from the short time available in most cases for the spread and growth of metastases.
The strategy of therapy
To what extent can this study assist in planning treatment?
1. All cases of osteosarcoma must be regarded as systemic disease, the majority of tumours having already spread beyond the primary site at the time of diagnosis. Lung metastases in
